Showing papers on "Cancer research published in 2009"

A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status

Abstract: 8073 Background: IPI-504 (retaspimycin hydrochloride) is a potent, water-soluble heat shock protein 90 (Hsp90) inhibitor. IPI-504 causes the degradation of mutated epidermal growth factor receptor ...

[Significance of beta-catenin and Cyclin D1 express in glioma].

Abstract: AIM: To investigate the expression and the significance of beta-catenin and Cyclin D1 in gliomas. METHODS: The SABC immunohistochemistry were used to detect the expression of beta-catenin and Cyclin D1 in 49 brain gliomas and 5 normal brain tissues. RESULTS: The beta-catenin positive ratio in normal brain tissues and glioma samples are 2/5 and 38/49(P<0.01) respectively, and the Cyclin D1 positive ratio in normal brain tissues and gliomas are 1/5 and 42/49(P<0.01); Compared with the normal brain tissue, both the immunohistochemical expression of beta-catenin and Cyclin D1 were up-regulated(P<0.05), and the expression of beta-catenin and Cyclin D1 between the normal brain tissues and gliomas exhibited significantly difference (P<0.01). CONCLUSION: beta-catenin and Cyclin D1 increased in gliomas may be precipitate the tumorigenesis of glioma.

Expression of SLC transporters in Chronic Lymphocytic Leukaemia cells and their interaction with cytostatics

Abstract: Chronic Lymphocytic Leukaemia, CLL, is one of the most common forms of leukaemia in the elderly. The treatment regimen determines the outcome of patients with CLL and the efficiency of this treatment is modulated by the concentration of cancer treating drugs in cancer cells. Uptake transporters of the SLC (solute carrier) family can help overcome chemoresistance by the application of transporter-specific cytostatics. In the present study, we investigated the expression of SLC transporters in six lymphoma cell lines and in CLL patient samples. Five of the six cell lines tested, as well as samples from CLL patients demonstrated a higher expression of SLC22A1 (OCT1) than in healthy lymphocytes. The uptake of the organic cation [3H]MPP into OCT1 stably transfected CHO cells was significantly inhibited by irinotecan, mitoxantrone and paclitaxel. The Ki values as determined using Dixon plot analyses were 1.71